Latest Breaking News On - Posterior reversible encephalopathy syndrome - Page 6 : comparemela.com
Prostate Cancer Screenings on the Decline with Concerns Surrounding COVID-19: What Men Should Know
murfreesboropost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from murfreesboropost.com Daily Mail and Mail on Sunday newspapers.
Prostate Cancer Screenings on the Decline with Concerns Surrounding COVID-19: What Men Should Know
berkshireeagle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from berkshireeagle.com Daily Mail and Mail on Sunday newspapers.
Prostate Cancer Screenings on the Decline with Concerns Surrounding COVID-19: What Men Should Know
ktbs.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ktbs.com Daily Mail and Mail on Sunday newspapers.
Prostate Cancer Screenings on the Decline with Concerns Surrounding COVID-19: What Men Should Know
Feb. 22, 2021
FacebookTwitterEmail
(BPT) - In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in
Takeda Pharmaceutical Company Limited
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
Saturday, December 19, 2020 2:19PM IST (8:49AM GMT)
– Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to CP-CML Patients with Resistance or Intolerance to At Least Two Prior Tyrosine Kinase Inhibitors (TKIs) –
– Approval Based on Data from the Phase 2 OPTIC Trial, Which Evaluated Response-Based ICLUSIG Dosing Regimens in CP-CML –
– New Dosing Regimen in CP-CML Optimizes Benefit-Risk Profile, Providing Efficacy and Improving Safety –
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG